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Abstract Acute heart failure (AHF) is characterized by
high morbidity and mortality and high costs. Although the
treatment of AHF has not changed substantially in recent
decades, it is becoming clear that treatment strategies for
AHF need to address both the immediate hemodynamic
abnormalities giving rise to congestion as well as prevent
organ damage that can influence long-term prognosis.
Serelaxin, the recombinant form of human relaxin-2, a
naturally occurring peptide hormone, has been found to
significantly improve symptoms and signs of AHF, prevent
in-hospital worsening heart failure, as well as significantly
improve 180-day cardiovascular and all-cause mortality
after a 48-h infusion commenced within 16 h of presenta-
tion (RELAX-AHF study). Available data suggest that the
clinical benefits may be attributable to a potential combi-
nation of multiple actions of serelaxin, including improving
systemic, cardiac, and renal hemodynamics, and protecting
cells and organs from damage via anti-inflammatory, anti-
cell death, anti-fibrotic, anti-hypertrophic, and pro-angio-
genic effects. This manuscript describes the short- and
long-term effects of serelaxin in AHF patients, analyzing
how these effects can be explained by taking into account
the range of hemodynamic and non-hemodynamic actions
of serelaxin. In addition, this paper also addresses several
aspects related to the role of serelaxin in the therapy of
AHF that remain to be clarified and warrant further
investigation.
1 Introduction
Heart failure (HF) is thought to affect approximately 15
million patients in Europe and 5 million in the USA [1, 2].
HF places a large burden on patients and healthcare sys-
tems [1, 3, 4], and hospitalization for acute HF (AHF)
contributes to much of the economic burden [1]. There are
more than 1 million hospitalizations for AHF each year in
the USA [2], and each hospitalization for AHF costs in the
region of $US19,000 [5]. AHF is associated with high rates
of subsequent mortality and hospital readmission, and is an
increasing problem due to an aging population and the
increasing prevalence of risk factors [1, 6–9]. Treatment of
AHF has not changed substantially in recent decades, and
major trials with new therapies have failed, likely due to a
poor understanding of the pathophysiology of AHF, as well
as an insufficient knowledge of the mechanisms of action
of the new agents used to treat patients with AHF [10].
AHF is a syndrome the pathophysiology of which is
complex and not fully understood, probably due to the lack
of adequate experimental models of AHF. It is now known
that it involves not only impaired hemodynamic function,
but also neurohormonal activation, inflammation, and
oxidative stress, which can promote myocardial, renal, and
hepatic injury and remodeling [11–13]. This multi-organ
damage may accelerate disease progression and impact
long-term prognosis. Indeed, many existing and emerging
markers of cardiac and extra-cardiac injury confirm that
such damage is associated with worse long-term outcomes
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in AHF [14–30]. Therefore, it appears that treatment
strategies for AHF need to address both the immediate
hemodynamic abnormalities, giving rise to dyspnea and
congestion, as well as prevent organ damage, by addressing
the myocardial and extra-cardiac cell injury and remodel-
ing that influence long-term prognosis.
Serelaxin is the recombinant form of human relaxin-2, a
naturally occurring peptide hormone that mediates sys-
temic hemodynamic and renal adaptive changes during
pregnancy [31]. Serelaxin mediates its actions by binding
to a member of the G-protein-coupled receptors known as
relaxin family peptide (RXFP) receptors, that are located in
heart tissue, blood vessels, and the kidneys [31, 32].
Binding of serelaxin to its RXFP1 receptor activates mul-
tiple signaling pathways promoting systemic and renal
hemodynamic effects [32, 33]. However, serelaxin also
appears to have multiple additional effects in the cardio-
vascular (CV) system and other organs, including anti-
inflammatory, anti-cell injury/death, anti-fibrotic, anti-
hypertrophic, and pro-angiogenic effects [33–35]. The
combination of the hemodynamic and organ-protective
effects of serelaxin may contribute to the short- and long-
term benefits of this agent in AHF, as shown in a recent
phase III study of serelaxin in AHF, the RELAX-AHF
(RELAXin in Acute Heart Failure) study.
This review aims to outline the clinical data with ser-
elaxin in patients with AHF, integrating and extrapolating
the available mechanistic data that could help to explain
both the short- and long-term clinical effects observed with
this novel agent. Some of these mechanistic studies have
investigated the effects of non-human forms of relaxin-2
instead of serelaxin (recombinant human relaxin-2), and
where possible this review tries to highlight the form used
(e.g. porcine relaxin-2 vs serelaxin). This review also
provides a critical analysis of the issues still pending
clarification regarding the role of serelaxin in the therapy of
AHF.
2 Clinical Effects of Serelaxin in Patients with Acute
Heart Failure (AHF)
2.1 Short-Term Effects
RELAX-AHF was a phase III, multicenter, randomized,
double-blind, placebo-controlled study designed to inves-
tigate the efficacy and safety of serelaxin in the treatment
of AHF [36, 37]. Patients hospitalized for AHF with sys-
tolic blood pressure (SBP)[125 mmHg, mild-to-moderate
renal impairment, and increased levels of N-terminal pro-
B-type natriuretic peptide (NT-proBNP) were randomized
within 16 h to serelaxin (30 lg/kg/day as a 48-h
intravenous infusion) or placebo (both on top of standard of
care). Serelaxin significantly reduced the short-term effects
of AHF, including symptoms and signs of congestion
during hospitalization and in-hospital outcomes, compared
with placebo. Serelaxin significantly improved the primary
efficacy endpoint of dyspnea relief through day 5 assessed
by the visual analog scale compared with placebo
(p = 0.007). It also provided a numerical, but not statisti-
cally significant, improvement in dyspnea relief assessed
by the Likert scale at 6, 12, and 24 h [36]. Serelaxin-treated
patients experienced significant improvements in other
symptoms and signs of AHF (dyspnea on exertion,
orthopnea, edema, rales) at day 2 compared with placebo-
treated patients. Consistent with prompt decongestion,
serelaxin treatment was associated with significantly lower
NT-proBNP levels at day 2 compared with placebo
(p \ 0.001) [36]. In terms of in-hospital measures, signif-
icantly fewer serelaxin-treated patients experienced in-
hospital worsening HF through day 5 compared with pla-
cebo (p \ 0.001) and serelaxin treatment was associated
with a significantly shorter length of hospital stay
(p = 0.0039) [36].
2.2 Long-Term Effects
An interesting observation from the RELAX-AHF study
was that although serelaxin did not reduce the composite
secondary endpoint of CV death or hospitalization at day
60, it reduced, by 37 %, both CV death (p = 0.028) and
all-cause mortality at day 180 (p = 0.02) [36]. All-cause
mortality and CV mortality were not primary endpoints of
the RELAX-AHF study and therefore these data need to be
confirmed in an appropriately designed, prospective trial.
However, the effect on all-cause mortality at day 180 with
serelaxin was consistent with findings from the phase II
pre-RELAX-AHF study (Fig. 1; [14]), which also reported
a numerical reduction in 180-day CV and all-cause mor-
tality with serelaxin versus placebo [38]. Of note, the
effects of serelaxin on outcomes were similar across sub-
groups of patients based on pre-specified covariates (age,
sex, race, geographic region, estimated glomerular filtra-
tion rate [eGFR], time from presentation to randomization,
baseline SBP, history of diabetes, atrial fibrillation, ische-
mic heart disease, cardiac devices, intravenous nitrates at
randomization) [39] or ejection fraction (either preserved
or reduced) [40]. The reduction in mortality at 180 days in
RELAX-AHF occurred despite serelaxin being adminis-
tered for only 48 h during the episode of acute decom-
pensation [36]. This final observation raises interesting
questions about how a short-term treatment may impact
long-term consequences in AHF, as discussed in the fol-
lowing section.
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3 Potential Mechanisms of Action of Serelaxin
in Patients with AHF
3.1 Rationale for Short-Term Effects
Insights into the possible mechanisms involved in these
short-term effects of serelaxin are given by the interpreta-
tion of results of earlier clinical studies. In a study of stable
patients with compensated HF, serelaxin provided hemo-
dynamic improvements, including reduced pulmonary
capillary wedge pressure (PCWP) and systemic vascular
resistance (SVR), and increased cardiac index, suggesting
it may reduce cardiac overload and improve cardiac per-
formance [41, 42]. Similarly, reductions in SVR and
PCWP and increases in cardiac index have been observed
with serelaxin in patients with AHF [43]. Serelaxin has also
been shown to increase renal plasma flow, and reduce renal
vascular resistance in rats [44] and in healthy volunteers
[45], suggesting it may increase renal perfusion. Such
improvements in myocardial and renal function will
decrease preload and afterload, leading to relief of the
symptoms and signs of congestion and renal impairment.
The hemodynamic effects of serelaxin appear to be
predominantly a consequence of receptor-mediated release
of nitric oxide and a reduction in endothelin-1 levels [34,
46], although emerging evidence suggests that angiogenic
growth factors (e.g. vascular endothelial growth factor
[VEGF]) may also contribute to the short-term effects of
serelaxin on vascular tone [47]. Interestingly, the vasore-
laxant effects of serelaxin are greater in vasoconstricted
blood vessels than in less constricted blood vessels [38,
48]. This has led to the suggestion that the natural hormone
is a regulator of vascular tone and protects against the
imbalances of vascular reactivity [49]. Indeed, unlike
diuretics, which appear to activate neurohormonal systems,
such as the renin-angiotensin-aldosterone system (RAAS)
[50–52], serelaxin appears to counteract the activation of
neurohormonal systems. For example, porcine relaxin-2
[53] and serelaxin [54] have been reported to blunt the
vasoconstrictive response and increase in systemic blood
pressure (BP) due to angiotensin II. In addition, serelaxin
has been shown to decrease SVR in rats with angiotensin-
mediated hypertension [55]. Importantly, the decline in
SVR elicited by serelaxin was offset by a corresponding
rise in cardiac output, thereby maintaining mean arterial
pressure (MAP) [55]. Thus, serelaxin mimics the vasodi-
latory influences of normal pregnancy, during which MAP
declines only slightly relative to the marked reduction in
SVR. This property of serelaxin may be particularly useful
to help preserve organ (e.g. renal) perfusion in conditions
of hemodynamic compromise and RAAS activation, such
as AHF.
Importantly, region-specific vascular effects of human
relaxin-2 (and, in turn, the recombinant hormone) may be
influenced by the cellular localization of RXFP1 receptors
within different blood vessels. In a recent study performed
in rats, RXFP1 immunostaining in endothelial and vascular
smooth muscle cells was found to be higher in mesenteric
vessels than in other vascular beds [56]. Accordingly,
subcutaneous administration of serelaxin for 5 days in rats
was shown to reduce wall stiffness and increase volume
compliance in mesenteric arteries but not in the other
vessels examined. These changes were associated with
enhanced bradykinin-mediated relaxation and modification
in geometrical properties, but not compositional changes in
the extracellular matrix in mesenteric arteries. Therefore,
the mesenteric resistance artery appears to be a key target
for the vasorelaxant actions of serelaxin. The potential
relevance of this action in AHF is highlighted by the fact
that increased capacitance of mesenteric vessels may
facilitate a shift in volume from the systemic circulation to
the splanchnic reservoir, decreasing effective circulatory
volume and thereby relieving congestion [57]. This may
explain why symptomatic relief occurred without signifi-
cant weight loss in serelaxin-treated patients in RELAX-
AHF [36].




























Pre-RELAX-AHF: p = 0.16
RELAX-AHF: p = 0.02
Combined: p = 0.0076
Fig. 1 In the RELAX-AHF
study, serelaxin was associated
with a reduced risk of all-cause
mortality compared with
placebo. This effect was
consistent with that observed in
the phase II Pre-RELAX-AHF
study [14]). Reprinted from
Metra [14] copyright (2013),
with permission from Elsevier
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3.2 Rationale for Long-Term Effects
The mortality benefit observed with serelaxin may be
explained by various clinical and pre-clinical observations
indicating that it has a unique mechanism of action that has
the potential to influence the various pathological processes
occurring during decompensation, such as end-organ
damage, which drive long-term prognosis in AHF.
3.2.1 Effects Against Cell Injury/Death
In RELAX-AHF, serelaxin treatment reduced levels of
high-sensitivity cardiac troponin T compared with stan-
dard of care, and fewer patients receiving serelaxin had
increases in cardiac troponin T compared with those
receiving placebo (Fig. 2 [14]). In addition, elevations
in cardiac troponin T [ 20 % from baseline were shown
to be associated with increased 180-day mortality
[14]. Thus, serelaxin appears to have cardioprotective
properties.
Serelaxin may promote myocardial cell preservation via
a number of different mechanisms. For example, serelaxin
has been found to have a number of anti-inflammatory
effects, including reducing inflammatory cell infiltration
into myocardial tissue following ischemia [58]. In addition,
serelaxin promotes cell survival by reducing oxidative
stress-mediated apoptosis, calcium overload, and infarct
size in animal models of ischemia/reperfusion injury
(Fig. 3) [33, 58]. By stimulating angiogenesis, and
improving stem cell survival and cell–cell coupling, ser-
elaxin may also facilitate myocardial tissue healing [33].
Of interest, recent evidence shows that serelaxin promotes
the maturation and proliferation of immature cardiomyo-
cytes [59], thus suggesting that it can participate in myo-
cardial regeneration. Consistent with these findings, in a
swine model of ischemia/reperfusion, serelaxin caused a
dose-related reduction of serum and tissue markers of
cardiomyocyte injury/death and leukocyte recruitment
(Fig. 3), with an accompanying overall improvement in
cardiac performance [58, 60].
Serelaxin may also provide protection against renal cell
damage. In RELAX-AHF, serelaxin provided significant
reductions from baseline in several markers of renal dys-
function (creatinine, blood urea nitrogen [BUN], and
cystatin C) through day 5. In addition, serelaxin signifi-
cantly reduced the incidence of worsening renal function
(defined as an increase from baseline in cystatin C
C0.3 mg/L or serum creatinine C0.3 mg/dL) compared
with placebo [14]. Interestingly, these measures of wors-
ening renal function were associated with increased
180-day all-cause mortality. This study also showed that
levels of uric acid, a marker of oxidative stress, inflam-
mation, and/or poor renal function associated with poor
prognosis in AHF [14, 61, 62], were reduced in patients
with AHF receiving serelaxin compared with placebo [14].
Consistent with these findings, acute serelaxin adminis-
tration has been shown to induce nitric oxide signaling
pathways and attenuate structural and functional injury,
oxidative stress, and neutrophil activation in a rat model of
kidney ischemia/reperfusion injury [63].
In RELAX-AHF, serelaxin administration was associ-
ated with reduced levels of transaminases [14], suggestive
of a hepatoprotective effect. Of interest, increases in serum
transaminases of C20 % from baseline to day 2 were
associated with increased 180-day all-cause mortality [14].
In addition, patients treated with serelaxin experienced
fewer adverse events classified as hepatobiliary disorders
than those treated with placebo (0.2 vs. 1.8 %, respec-
tively; odds ratio 0.10 [95 % confidence interval (CI)
0.01–0.77]) [14]. Such benefits may be explained not only
by an offloading effect (i.e. alleviating hepatic congestion),
but also by a direct cytoprotective effect in the liver.
Experiments to simulate liver transplantation in rats, for
example, have shown that addition of serelaxin to the
preservation solution could reduce markers of cell damage
compared with controls [64, 65]. Using a model of isolated
*p < 0.05 vs. placebo by repeated measures analysis of variance with adjustment for baseline value



































































n/N =   145/534 86/522
baFig. 2 In patients with acute
heart failure in the RELAX-
AHF study, serelaxin was
associated with lower levels of
high-sensitivity cardiac troponin
levels (hs-cTnT) (a) and a
reduced incidence of patients
with an elevation (C20 % from
baseline) in hs-cTnT
(b) compared with placebo
[14]). Reprinted from Metra
[14] (Fig. 3a), copyright (2013),














































































*p < 0.05; ***p < 0.001 vs. sham-operated; a=p < 0.05 vs. I-R; b=p < 0.01 vs I-R; c=p < 0.001 vs. I-R
Total caspase-3 activity and






































***p < 0.001 vs. sham-operated; b=p < 0.01 vs. I-R; c=p < 0.001 vs. I-R

































Fig. 3 Serelaxin reduces inflammatory leukocyte recruitment and
oxygen free radical-mediated cardiomyocyte injury (a), apoptosis of
cardiomyocytes (assessed by caspase-3 activity and TUNEL [Termi-
nal deoxynucleotidyl transferase dUTP nick end labeling] assay)
(b) and markers of cardiomyocyte injury (creatine kinase MB
isoenzyme [CK-MB] and troponin T) (c) in an in vivo porcine model
of ischemia/reperfusion [58]. Sham operated animals (n = 5); all
other groups (n = 8). Sham-operated = negative control;
I-R = ischemia-reperfusion = positive control (vehicle only). Rep-
rinted from Perna [58], Federation of American Societies for
Experimental Biology (FASEB) copyright (2005)
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perfused rat liver, the same group has demonstrated that
serelaxin administration improved oxygen supply (as
assessed by spectrophotometric imaging) and decreased
myeloperoxidase and malondialdehyde activities (as
assessed by immunohistochemistry) compared with control
[64]. These findings indicated that serelaxin can protect the
liver by improving oxygen distribution and reducing
inflammation and oxidative stress, an effect that could also
be beneficial in AHF.
3.2.2 Effects Against Tissue Fibrosis
By protecting cells and organs from damage, serelaxin
may indirectly reduce the consequent reparative response
and fibrosis. In addition, serelaxin may have direct anti-
fibrotic effects, and preclinical studies have shown that
serelaxin can inhibit collagen synthesis and promote
collagen breakdown of cardiac fibroblasts (Fig. 4) [66–
68]. In a study using relaxin gene-knockout (RLX-KO)
mice, the RLX-KO mice underwent progressive increases
in cardiac and renal collagen content compared with wild-
type animals. However, serelaxin treatment for 14 days in
RLX-KO mice in the early or developed stages of fibrosis
caused the reversal of collagen deposition in the heart and
kidneys [69]. In a mouse model of reparative fibrosis after
a myocardial infarction, treatment with a serelaxin infu-
sion for 7 or 30 days significantly reduced collagen den-
sity in the infarcted and border zones, without increasing
the risk of ventricular rupture due to collagen breakdown,
compared with mice treated with vehicle control (Fig. 4)
[70, 71]. In addition, serelaxin treatment was associated
with reduced cardiac fibroblast differentiation and car-
diomyocyte apoptosis, as well as the induction of de novo
blood vessel growth [70]. This suggests that serelaxin
may regulate reparative fibrosis without adverse conse-
quences, enabling subsequent myocardial healing. The
effect of serelaxin on fibrosis appears to be achieved via
Notch-1-mediated inhibition of the pro-fibrogenic effects
of the transforming growth factor (TGF)-b/p-Smad axis
[72]. Serelaxin appears to upregulate matrix metallopro-
teinases (MMPs) and downregulate tissue inhibitors of
metalloproteinases (TIMP) [67, 68], thus facilitating the
removal of fibrotic tissue. This effect of serelaxin on
MMPs appears to occur via inducible nitric oxide syn-
thase signaling, as evidenced by studies in TGF-b1-
stimulated human dermal fibroblasts and primary renal
myofibroblasts isolated from injured rats that were incu-
bated with serelaxin or control for 72 h [73]. In contrast to
these findings, a study in spontaneously hypertensive rats
suggests that, although 2-weeks of treatment with serel-
axin reverses myocardial fibrosis, this effect is not asso-
ciated with increased expression of the gelatinases, MMP-
2 or MMP-9 [74].
Serelaxin may have anti-fibrotic effects in the liver.
Increased expression of the RXFP1 receptors has been
observed in fibrotic liver disease [75]. In human cultured
hepatic stellate cells, a 72-h treatment with serelaxin has
been reported to induce an anti-fibrogenic phenotype [75].
Furthermore, treatment of activated cultured hepatic stel-
late cells from rat liver with porcine relaxin-2 for 24–48 h
reduces collagen, increases secretion of TIMP-1, TIMP-2,
and MMP-13, and inhibits the synthesis of new collagen
compared with cells not treated with relaxin-2 [76]. In an
in vivo mouse model of hepatic fibrosis, 1 week of treat-
ment with porcine relaxin-2 was reported to reduce colla-
gen and smooth muscle actin content and significantly
reduce serum levels of hepatic transaminases [77]. A sub-
sequent study utilizing the same model has shown that
reductions in fibrosis with 4 weeks of treatment with ser-
elaxin were associated with increases in MMP-13,
decreases in TIMP-2, and impaired TGF-b signaling
compared with vehicle [78].
Whether this anti-fibrotic effect of serelaxin is clinically
important in AHF remains to be clarified. It is notable that
many of the preclinical studies showing anti-fibrotic effects
of serelaxin in vivo occurred when serelaxin was admin-
istered for durations longer than the 48-h infusion used in
AHF clinical studies [66, 70, 74, 78]. However, in vitro
studies have shown that anti-fibrotic actions of serelaxin
can manifest even within 24–72 h [66, 68, 75].
4 Unresolved Issues
Notwithstanding the promising findings of the RELAX-
AHF study, there are several issues still pending to be
clarified for a better understanding of the role of serelaxin
in the therapy of AHF.
4.1 Pharmacological Issues
In the RELAX-AHF study, congestion and biomarkers of
end-organ damage, which were strongly associated with
increased 180-day mortality, were relieved by an early 48-h
intravenous infusion of serelaxin, and 180-day mortality
was reduced. Hence, it is possible that early treatment of
AHF, including decongestion and prevention of damage to
the heart, kidneys, and liver, is critical to preventing long-
term mortality in AHF. The emerging question is how an
early short-term administration of serelaxin is translated
into long-term clinical benefit in AHF patients. The ability
of a short-term infusion to have a beneficial long-term
effect on outcomes has already been clearly shown in the
area of thrombolytics in acute coronary syndromes [79]. In
addition, it is also possible that the effects of serelaxin
persist beyond the initial infusion, providing a greater
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window of decongestion and organ protection during the
acute event. The terminal half-life of an intravenous bolus
of serelaxin is reported to be 4.6 h in healthy individuals
[80], and studies in patients with AHF have shown that
reductions in SVR with serelaxin were present up to 4 h,
and changes in blood pressure and NT-proBNP were
present up to 24 h, after cessation of the infusion [43].
Similarly, a study in patients with chronic HF has also
reported that hemodynamic effects can persist, lasting up to
8 h after termination of the infusion [42].
Therefore, the possibility exists that the ability of ser-
elaxin to intercept hemodynamic and end-organ damaging
mechanisms activated at earlier stages of AHF is translated
to further reduction in the burden of long-term mortality.
Indeed, the beneficial effects observed with serelaxin in
preclinical studies (Table 1) suggest that, when it is
administered even for a short (48-h) period early during
AHF, serelaxin may interrupt the cascade of pathophysio-
logical processes that are triggered during an acute
decompensation and drive the long-term consequences of
AHF (Table 1).
Unfortunately, there are no good experimental models
of AHF to better understand the pathophysiology of this
syndrome or assess the effects of new therapies. In the
absence of good models, information has been extrapolated
from observations in other experimental models that may
*p < 0.05, **p < 0.01 vs. untreated cells
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Atrial fibroblasts Ventricular fibroblasts Atrial fibroblastsa
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Fig. 4 Serelaxin modulates cardiac collagen deposition in vitro
(a) and in vivo (b). a Collagen content of in vitro fibroblasts,
untreated/treated with serelaxin (100 ng/mL) alone or with trans-
forming growth factor-b (2 ng/mL) or angiotensin II (10–7 M), for
72 h of culture. Results are mean data from 3–4 separate experiments
[66]. Reprinted with permission from Samuel [66] with permission
from the Endocrine Society, copyright (2004). b Collagen density
(mean ± SE) estimated by computer-aided morphometry and MMP-
13 density (expressed as a percentage per field) from eight fields
representing the non-infarct region, border region, and infarct region
from the lower mid-zone of hearts from a mouse model of myocardial
infarction (n = 9–12/group) [70]. Reprinted by permission from
Macmillan Publishers Ltd: Laboratory Investigation [70], copyright
(2011). Ang angiotensin, BR border region, IR infarct region, MI
myocardial infarction, MMP matrix metalloproteinase, NIR non-
infarct region, SE standard error, TGF transforming growth factor
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be of relevance to AHF. Given these limitations, it is
unclear what the relative contributions are for the various
vasorelaxant, anti-inflammatory, anti-oxidative stress, cy-
toprotective, anti-fibrotic, and angiogenic mechanisms in
contributing to the effect of serelaxin on long-term out-
comes in AHF. While it is possible that some of these
effects are secondary to vasorelaxation and improved organ
perfusion, it is worthwhile to note that nitrate vasodilators
have not been shown to improve long-term outcomes in
AHF [81, 82]. Moreover, cytoprotective, anti-inflamma-
tory, and anti-fibrotic effects of serelaxin have been
observed in vitro [68, 83–87], suggesting that there could
be a component of these actions that is not dependent upon
modulation of vascular tone. The need for further explo-
ration in this area is clearly warranted.
4.2 Pathophysiological Issues
Increased plasma levels of relaxin have been reported in
patients with chronic HF of different etiologies [88–90].
Interestingly, patients with chronic HF, but not controls,
show a transcardiac relaxin gradient [91], as well as a
gradient of relaxin from the coronary blood to the periph-
eral blood [90]. Collectively, these data suggest that the
failing heart is a source of the excess of circulating relaxin
present in patients with chronic HF. Of interest, RXFP
receptors do not internalize following prolonged exposure
to relaxin [92], and it may be anticipated that the physio-
logical actions of the peptide/receptor complex will be
preserved, even in the presence of high systemic levels of
relaxin/serelaxin. Further studies are required to ascertain
whether reduced cardiac synthesis and secretion of relaxin
precedes and triggers AHF, thus explaining the favorable
effects of serelaxin in patients with this condition.
4.3 Clinical Issues
Although treatment with serelaxin did reduce CV and all-
cause mortality by 37 % at 180 days, it did not reduce the
incidence of readmission to hospital owing to HF, renal
failure, or CV death, nor did it significantly increase sur-
vival, up to 60 days after hospital discharge. Although data
from classical studies suggested that rehospitalization has
historically been regarded as a risk factor for mortality [93–
96], recent data have shown a poor correlation between the
two [97]. Indeed, mortality may represent a competing risk
factor for rehospitalization [98, 99]. In addition, short-term
rehospitalizations might also be related to non-modifiable
factors, such as social support, geographic location, and
socioeconomics, so that there is a discrepancy between
early readmissions and post-discharge mortality [100]. On
the other hand, it must be remarked that the RELAX-AHF
trial was neither designed nor powered to assess mortality
as an endpoint. Therefore, because the mortality data in the
RELAX-AHF trial emerge as an hypothesis-generating
issue, an appropriately powered trial has been undertaken
to replicate them (the RELAX-AHF-2 study comprising
[6,000 patients with AHF) [101].
5 Conclusions and Perspectives
Current therapies are moderately effective at relieving the
symptoms and signs of congestion by addressing the
hemodynamic changes associated with AHF, but have not
demonstrated any benefit on long-term outcomes, pre-
sumably because they have limited effects on the under-
lying pathophysiology and fail to protect organs from
damage in AHF. Recently, serelaxin, the recombinant form
of human relaxin-2, was shown to relieve symptoms and
signs of AHF, as well as reducing CV and all-cause mor-
tality in the phase III RELAX-AHF study in patients with
AHF. This is particularly promising, as serelaxin is the
only agent demonstrated to improve mortality in a large
randomized controlled trial of patients with AHF, although
this was not a primary endpoint of the study.
Initial data suggest that the clinical benefits observed in
RELAX-AHF may be explained by the effect of serelaxin
on the multiple pathophysiological processes that drive the
short- and long-term consequences of AHF. Indeed, myo-
cardial cell injury/death and fibrosis may be triggered
during an AHF episode, which may lead to further cardiac
Table 1 Summary of the cardiac, vascular, and cytoprotective effects
of serelaxin/relaxin-2 (modified from Du et al. [33])
Overall effect Mechanisms involved
Vasorelaxation : NO production
; Vasoconstriction via ET-1
: Vasodilation via ET1–32/ETB receptor
: Angiogenic growth factors
Anti-inflammatory
effects




; Cardiomyocyte-stimulated protein synthesis
: ANP expression











: Integrity of plasma membrane and
mitochondrial membrane
; Cardiomyocyte apoptosis
ANP atrial natriuretic peptide, ET endothelin, NO nitric oxide
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dysfunction and poor prognosis in the long term. Pre-
clinical data suggest that serelaxin can interrupt these
processes, protecting organs from damage and improving
hemodynamics, which may explain the clinical observation
that short-term (48-h) administration of serelaxin early in
the AHF episode reduced 180-day mortality compared with
placebo.
Further studies with serelaxin are warranted to both
translate the experimental information of its actions to
humans, and to confirm its beneficial added value in the
treatment of patients with AHF.
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